The GSK share price jumps 6% on positive FY 2024 results. Is it a stock to consider now?

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results. 

| More on:
A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GSK share price rallied 6% this morning after the company published a surprisingly strong set of full-year results for 2024. Many metrics beat analysts’ expectations, including sales and revenue.

The multinational pharmaceutical and biotechnology company had a tough year, with an extended drop in vaccine sales. However, total sales still rose 8% to £31.4bn, with particularly strong growth in Speciality Medicines (up 19%). 

For the full year, core operating profit climbed 11% to £9.1bn and core earnings per share (EPS) rose 10% to 159.3p. Notably, both metrics were down 10% compared to Q4 2023.

The firm announced a Q4 dividend of 16p, bringing the full-year dividend up to 61p. To top it off, a £2bn share buyback programme was announced, to be carried out over the next 18 months.

2025 guidance

CEO Emma Walmsley said: “We expect another year of profitable growth in 2025, and have further improved our long-term outlook, with sales of more than £40bn now expected by 2031.

She went on to highlight how the company is increasing and prioritising investment in research and development. A focus on new long-acting and speciality medicines was noted, specifically in Respiratory, Immunology & Inflammation, Oncology and HIV. Last year already saw 13 positive phase-three readouts in these areas, strengthening the company’s pipeline progress.

A key driver in today’s price growth was likely the company’s decision to boost forward guidance. It now expects turnover growth in 2025 to be between 3% and 5%, with core operating profit growth of between 6% and 8%. Core EPS is expected to follow a similar pattern, benefiting from share buybacks.

The sales outlook for 2031 has now been increased to more than £40bn (previously £38bn), reflecting late-stage pipeline progress.

A big factor that ate into profits last year was a £2.2bn settlement regarding ongoing Zantac lawsuits. Despite the payment, not all cases are settled and more may still arise. The threat of product-related lawsuits is a constant risk that pharmaceutical companies must navigate. 

Another key risk is the proposal by the Trump administration to make Robert F Kennedy Jr. the US health secretary. Based on past comments made by Kennedy, some medical professionals feel he is a vaccine sceptic. With the US as one of its key markets, his influence could hurt the company’s profits.

Signs of a recovery

Shareholders have been losing faith in GSK over the past few years, with the share price leaving little to get excited about. Since early 2020, it’s made two impressive recoveries to £18, only to crash again to £13 soon after.

One of those crashes came in July 2022 after the company demerged from its consumer healthcare business, Haleon. Intended to allow the company to focus on pharmaceuticals, the move shook investor confidence. The shock was further compounded by a 27.8% dividend cut that took the 2022 full-year payment down from 80p to 57.7p per share.

With sales up and the dividend growing once again, this may be early evidence that the decision is paying off. It still faces some challenges but I think today’s results make it a stock worth considering.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Mark Hartley has positions in GSK. The Motley Fool UK has recommended GSK and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How much does an investor need in a Stocks and Shares ISA to earn £1,000 a month in passive income?

A Stocks and Shares ISA's a valuable asset for investors. Not having to pay dividend tax can be a big…

Read more »

Investing Articles

9% dividend yield! Could buying this FTSE 250 stock earn me massive passive income?

Assura looks like an outstanding stock for dividend investors to consider. But is the 9% dividend yield the passive income…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Why I think this month could be critical for the Lloyds share price!

Our writer explains why he thinks the bank's 2024 results will have a significant impact on the short-term direction of…

Read more »

British Pennies on a Pound Note
Investing Articles

This former penny share has soared 168%. Is the best yet to come?

When Christopher Ruane saw a penny share as a potential bargain last year, he was spot on. So having not…

Read more »

Mature couple at the beach
Investing Articles

£20k in an ISA? Here’s how it could generate £1 of passive income every hour — forever

With a long-term approach, Christopher Ruane explains how an investor could aim to earn a pound per hour in passive…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

FTSE shares: overpriced or still a bargain?

Christopher Ruane reckons a storming FTSE 100 performance of late doesn't tell us much about whether there are still possible…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Would an investor have made money investing £2k in NIO stock 5 years ago?

Our writer looks at how NIO stock has performed over recent years and weighs the bull and bear cases as…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

5 steps to start buying shares with £5 a day

In a handful of steps, our writer explains how someone new to the stock market could start buying shares for…

Read more »